About the Authors
- Anastasia Wyce
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Gopinath Ganji
-
Affiliation Molecular Medicine Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Kimberly N. Smitheman
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Chun-wa Chung
-
Affiliation Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom
- Susan Korenchuk
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Yuchen Bai
-
Affiliation Molecular Medicine Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Olena Barbash
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- BaoChau Le
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Peter D. Craggs
-
Affiliation Platform Technology and Science, GlaxoSmithKline, Stevenage, United Kingdom
- Michael T. McCabe
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Karen M. Kennedy-Wilson
-
Affiliation Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Lydia V. Sanchez
-
Affiliation Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Romain L. Gosmini
-
Affiliation Lipid Metabolism Discovery Performance Unit, GlaxoSmithKline, Les Ulis, France
- Nigel Parr
-
Affiliation Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom
- Charles F. McHugh
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Dashyant Dhanak
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Rab K. Prinjha
-
Affiliation Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom
- Kurt R. Auger
-
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
- Peter J. Tummino
-
* E-mail: Peter.J.Tummino@gsk.com
Affiliation Cancer Epigenetics Discovery Performance Unit, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America
Competing Interests
The authors have read the journal's competing interest policy and have the following conflicts to disclose: all authors are current or former employees of GlaxoSmithKline. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: AW PC KS CC SK RP DD KA PT. Performed the experiments: AW SK KS BL CC PC RG YB MTM. Analyzed the data: AW GG KS CC SK BL CM YB MTM. Contributed reagents/materials/analysis tools: KKW LS RG NP. Wrote the manuscript: AW OB KA PT.